<DOC>
	<DOCNO>NCT02876796</DOCNO>
	<brief_summary>The primary objective study assess pharmacodynamic ( PD ) effect GS-0976 ( NDI-010976 ) fractional de novo lipogenesis ( DNL ) follow single oral dose administration overweight and/or obese , otherwise healthy , male adult .</brief_summary>
	<brief_title>Study Evaluate Pharmacodynamic Effects Single Oral Dose GS-0976 ( NDI-010976 ) Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Overweight and/or obese , otherwise healthy male Weight â‰¥ 50.0 kg Body Mass Index ( BMI ) : 25.0 32.0 kg/m^2 , inclusive Intolerance malabsorption fructose A history clinically significant gastrointestinal disease and/or surgery , would result subject 's inability absorb metabolize study drug ( e.g. , gastrectomy , gastric bypass , cholecystectomy ) . In opinion Investigator , history clinically significant hematologic , renal , hepatic , bronchopulmonary , neurological , psychiatric , metabolic , endocrine disorder ( e.g. , diabetes , thyroid disease ) , cardiovascular disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>fractional de novo lipogenesis</keyword>
	<keyword>DNL</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>